Event Participants
Executives
4 Abhishek Singhal, Haribabu Bodepudi, Rajaram, Ramakant Singani
Analysts
7 Bharath Seth, Chintan Seth, Kumar Saurabh, Sahil Sanghi, Sajal Kapoor, Shubham Agrawal (plus one unidentified analyst)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹946 crores | +19.5% YoY, +2.9% QoQ; sustained double-digit growth across segments |
| Gross Margin | 54.1% | +220 bps YoY vs 51.9% in Q1FY26; mix improvement from backward integration |
| EBITDA | ₹205 crores | +59.2% YoY; margin 21.6%, +530 bps YoY vs 16.2% |
| Profit Before Tax | ₹112 crores | +132% YoY (vs ₹48 crores Q1FY26); after ₹19 crores incremental ESOP expense |
| Profit After Tax | ₹79 crores | +115% YoY (vs ₹37 crores Q1FY26) |
| Finance Costs | ₹12.5 crores | Down from ₹20.4 crores in Q1FY26; benefits of debt reduction |
| Net Debt | ₹86 crores | Down from ~0.24x Net Debt/EBITDA last quarter; ~1x a year ago to 0.1x now |
| ESOP Expense (Q1) | ₹25 crores | Includes ₹19 crores incremental grant of 1.3 crore options (2.8% of post-amalgamation capital) |
Geographic & Segment Commentary
Animal Health Formulations: Strong growth across all regions including 60% growth in domestic market; expansion of field force and product portfolio planned. R&D ramped up for companion animal products with new manufacturing plant targeted for January-February completion for exhibit batches.
Human Health Formulations (US): Revenue grew 60% YoY; strategy shift to backward-integrated complex products paying off - volume products moved to India, APIs integrated in-house, and one major launch captured 50-55% market share. EBITDA margins for this business at 34-35% expected to sustain.
European Region: Q1 flat on EUR basis (€16.8M vs €16.9M) but phasing-related; full-year growth expected at 18-20% on INR basis. Spain performing strongly; other building markets (e.g., Ireland) contributing gradually. Peak quarter typically Q3.
Emerging Markets: Grew ~36% (23% in USD terms); volume growth of 25% driven by Turkey, Brazil, Mexico. Turkey transitioning from pricing-led to volume-led growth with new product launches, pipeline remains strong.
API Business: Broadly flat QoQ due to raw material price volatility and customer wait-and-watch on war's trajectory; no business lost. Orders returning post-July; management expects Q2 FY27 to be best-ever quarter historically. API ~40% of top line (two-thirds human, one-third animal); animal health API growing 20%+.
Company-Specific & Strategic Commentary
BioForLife Acquisition (Italy): SPA signed; closing expected in 2-3 months subject to conditions. Brings 85 companion animal products, 85% wet clinic coverage in Italy, and local talent; strategic as launchpad for EU expansion with 18-24 months for cross-registrations into existing front-end markets.
Companion Animal Build-out: Core five-year strategic priority. New tablet capacity design finalized, construction starting within weeks, targeted for January-February operational readiness. Combined with BI partnership in India and R&D expansion, positions for bigger launches with full integration from FY29.
High Potent/Oncology Platform: R&D API capabilities built over 2 years; high potent formulation development lab completed last week. Partnered with strategic oncology manufacturer. 50% of portfolio first-to-file/first-to-launch; API revenue starting FY29, formulation revenue post-FY30. Brand opportunity >$20 billion, price erosion expected 50-60% for high potent vs 95% for commoditized APIs.
Balance Sheet Transformation: Net debt/EBITDA from ~1x a year ago to 0.1x; enables brownfield expansion and selective inorganic opportunities. Capex run-rate ₹250-300 crores per annum, manageable within existing cash flows.
Minority Interest Optimization: Evaluating buyout of minority stakes in US and Spain operations; target to reach 100% ownership within 1-2 years. Minority interest currently ~16-17% of consolidated profits (vs 20% FY26 full year).
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth (consolidated) | 13-15% for FY27 | Base growth; acceleration expected from FY29 with patent expiries and complex product launches |
| EU Growth | 18-20% full-year FY27 | Volume + pricing; Q1 softness is phasing not structural |
| EBITDA Margin | 20-22% | Consistent with prior guidance; maintained while investing in R&D and manufacturing |
| Animal Health API Growth | 20%+ | Capacity expansion at Vizag site (US approval received); commercialization started July |
| Human API Growth | 13-14% | Complex product launches weighted to FY28-FY29; day-one launch opportunities |
| ESOP Cost | ₹150 crores FY27; ₹25-30 crores FY28 | Multi-year amortization of one-time amalgamation grant; normalized thereafter |
| Depreciation | ~₹10-11 crores/quarter from Q2 FY27 | ₹15 crores quarterly benefit vs Q1 levels (₹25 crores); amortization of goodwill winding down |
| BioForLife Integration | Closing in 2-3 months; revenues in 18-24 months | Cross-registrations to other EU markets; 25-30% growth post-FY28-29 |
| $1 Billion Revenue | FY32 target | Implies ~18% CAGR from FY27 base; achievable through organic + inorganic mix |
| Minority Buyout | 100% ownership in 1-2 years | US and Spain subsidiaries; evaluating timing vs M&A opportunities |
Risks & Constraints
| Risk | Context |
|---|---|
| Raw Material Price Volatility | API customers deferred procurement during Q1 amid war-related uncertainty; management sees stabilization and order recovery, but continued geopolitical escalation could recreate delays |
| EU Market Execution | Quarterly volatility from tender-linked and vaccination-outbreak-dependent demand; cross-border registration timelines for BioForLife products may slip beyond 24 months |
| M&A Integration | Management acknowledges past Alvira experience; BioForLife is brand-led with no manufacturing, but guardrails include not "Indianizing" European operations, maintaining local teams, clear launchpad strategy |
| ESOP Dilution | 2.8% of post-amalgamation paid-up capital granted; one-time ₹19 crores incremental expense in Q1, full-year impact ₹150 crores, normalizing FY28 |
| Complex Product Delays | High potent/oncology revenue dependent on patent expiries (FY29-30+); regulatory or competitor timing shifts could postpone expected inflection point |
| Forex Exposure | Currency fluctuation impacts reported growth (EU ~18-20% INR vs EUR flat in Q1); depreciation of INR supports revenue but volatility creates quarterly noise |
Q&A Highlights
EU Growth Softness
- Question: EU revenue flat on EUR constant currency basis (€16.8M vs €16.9M); any concerns? (Unidentified, IIFL)
- Answer: Q1 phasing, not structural - Q3 typically peaks; contracts/tenders shift between quarters. Full-year expectation remains 18-20% growth on INR basis; volume + pricing + forex contribution. Spain very strong; newer EU markets building gradually. (Haribabu Bodepudi)
US Business Growth Drivers
- Question: US grew ~45-60% YoY on low base - sustainability? EBITDA margins improved from ~1% to 34-35% - continue? (Unidentified, IIFL)
- Answer: Strategy shift to backward integration - volume products moved from US manufacturing to India, APIs integrated in-house, one strong launch holding 50-55% market share. R&D stepped up. Margins expected to sustain; 60% growth not repeatable but stable growth with strong potential. (Haribabu Bodepudi)
API Flat Performance and Outlook
- Question: API flat - any business loss? (Sahil Sanghi, Monarch Networth)
- Answer: No business lost - customers held inventory awaiting war resolution and raw material price direction; orders returning post-July. Q2 FY27 expected to be best-ever quarter for API (both human and animal health). Animal health API to grow 20%+; consolidated API guidance 13-15%. (Haribabu Bodepudi)
ESOP Expense Run-Rate
- Question: ESOP cost clarification - ₹19 crores incremental in Q1, what next? (Sahil Sanghi, Monarch Networth)
- Answer: Total ESOP cost FY27 ~₹150 crores (Q1 ~₹25 crores, next 3 quarters ~₹40 crores each); FY28 drops to ₹25-30 crores. One-time grant tied to amalgamation at ₹230/share; normalizes thereafter. (Ramakant Singani)
High Potent/Oncology Platform
- Question: Current run-rate, capability, EBITDA margins for high potent? (Bharath Seth, Quest Investment)
- Answer: Oncology-focused platform - API R&D lab built over 2 years, high potent formulation development lab completed last week, manufacturing modules in place, strategic oncology manufacturing partner tied up. Revenue starts FY29 (API) and post-FY30 (formulation) given 5-7 year development lead time vs patent expiry. 50% of portfolio is first-to-file/launch. (Haribabu Bodepudi)
Depreciation and Interest Costs
- Question: How to model interest cost and depreciation going forward? (Bharath Seth, Quest Investment)
- Answer: Depreciation/goodwill amortization ₹25 crores in Q1; drops to ~₹10-11 crores from Q2 - ₹15 crores quarterly benefit. Ireland debt restructuring underway (Sequent India done last year), interest savings from next year; current rates at par with large pharma peers. (Haribabu Bodepudi)
Capital Allocation Principles
- Question: Non-negotiables as company moves to complex R&D, M&A, geographic expansion? (Sajal Kapoor, Antifragile Thinking)
- Answer: Three pillars - compliance (regulatory, statutory, quality, EHS) never compromised; governance never compromised; financial discipline with M&A only fitting strategic direction (companion animal, CDMO, complex areas). Not acquiring just to add numbers despite strong balance sheet. (Haribabu Bodepudi)
BioForLife Revenue Contribution
- Question: Top-line contribution from BioForLife in 1-2 years? (Mehul, 40 Cents)
- Answer: 18-24 months for cross-registrations into Spain, Turkey, Brazil where front-end exists; Italy contributes natural double-digit growth. Larger revenue inflection post-2 years; companion animal target $150-200 million by FY32. BioForLife serves as launchpad for Europe, not just its product portfolio. (Haribabu Bodepudi)
Minority Interest Outlook
- Question: How should we model minority interest? (Chintan Seth, Greek Capital)
- Answer: ~16-17% of profits in Q1 (vs 20% FY26 full year). Evaluating buyout of US and Spain minority stakes - expecting 100% ownership within 1-2 years, timing may align with M&A opportunities. (Haribabu Bodepudi, Ramakant Singani)
M&A Guardrails from Alvira Experience
- Question: European acquisitions historically costly post-deal (Alvira); guardrails for BioForLife? (Kiran, Table 3)
- Answer: Lesson learned - cannot "Indianize" European operations. BioForLife is brand-led, no manufacturing complexity; strategy is launchpad utilization with local teams. Recent Indian pharma European operations performing well; management confident on successful execution. (Haribabu Bodepudi)
Key Takeaway
Viyash Scientific delivered strong Q1 FY27 results with revenue of ₹946 crores (+19.5% YoY), EBITDA of ₹205 crores (+59.2% YoY, 21.6% margin), and PAT of ₹79 crores (+115% YoY), despite ₹19 crores of incremental one-time ESOP expense. The balance sheet reached its strongest-ever position with net debt of ₹86 crores (0.1x Net Debt/EBITDA, down from ~1x a year ago), enabling ₹250-300 crores annual capex and selective M&A. Strategic momentum centers on the BioForLife acquisition in Italy (closing in 2-3 months) as a companion animal launchpad for Europe, backward-integrated US formulation growth (60% YoY), high potent oncology platform positioning for FY29+ patent expiries, and minority buyouts in the US and Spain targeting 100% ownership within two years. API business, flat in Q1 due to customer deferrals, is expected to post its best-ever quarter in Q2 FY27. Management guided to 13-15% consolidated revenue growth for FY27, 20-22% EBITDA margins, EU growth of 18-20% on a full-year basis, and a $1 billion revenue target by FY32 implying ~18% CAGR. Key watchpoints include ESOP-related earnings drag normalizing in FY28, depreciation stepping down ~₹15 crores per quarter from Q2, and execution of 18-24 month registration timelines for BioForLife portfolio expansion.